id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0515-0003,FDA,FDA-2021-N-0515,Agency Information Collection  Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2022-01-28T05:00:00Z,2022,1,2022-01-28T05:00:00Z,,2022-01-28T17:26:40Z,2022-01692,0,0,0900006484f3ec59
FDA-2021-N-0515-0002,FDA,FDA-2021-N-0515,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Postmarketing Adverse Experience Reporting and Recordkeeping for Drug and Biological Products",Notice,30 Day Proposed Information Collection,2021-11-05T04:00:00Z,2021,11,2021-11-05T04:00:00Z,2021-12-07T04:59:59Z,2021-11-05T17:18:42Z,2021-24236,0,0,0900006484e23a30
FDA-2021-N-0515-0001,FDA,FDA-2021-N-0515,Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting and Recordkeeping for Drug and Biological Products,Notice,60 Day Proposed Information Collection,2021-06-30T04:00:00Z,2021,6,2021-06-30T04:00:00Z,2021-08-31T03:59:59Z,2021-06-30T13:06:23Z,2021-13968,0,0,0900006484bc2b95